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Abstract
Background: Mutations in parkin and PTEN-induced kinase 1 (Pink1) lead to autosomal recessive forms of
Parkinson’s disease (PD). parkin and Pink1 encode a ubiquitin-protein ligase and a mitochondrially localized serine/
threonine kinase, respectively. Recent studies have implicated Parkin and Pink1 in a common and evolutionarily
conserved pathway for protecting mitochondrial integrity.
Results: To systematically identify novel components of the PD pathways, we generated a genetic background
that allowed us to perform a genome-wide F1 screen for modifiers of Drosophila parkin (park) and Pink1 mutant
phenotype. From screening ~80% of the fly genome, we identified a number of cytological regions that interact
with park and/or Pink1. Among them, four cytological regions were selected for identifying corresponding PD-
interacting genes. By analyzing smaller deficiency chromosomes, available transgenic RNAi lines, and P-element
insertions, we identified five PD-interacting genes. Among them, opa1 and drp1 have been previously implicated in
the PD pathways, whereas debra (dbr), Pi3K21B and b4GalNAcTA are novel PD-interacting genes.
Conclusions: We took an unbiased genetic approach to systematically isolate modifiers of PD genes in Drosophila.
Further study of novel PD-interacting genes will shed new light on the function of PD genes and help in the
development of new therapeutic strategies for treating Parkinson’s disease.
Background
Parkinson’s disease (PD) is the second most common
neurodegenerative disease. It is characterized by the loss
of nigral dopaminergic neurons. Mutations in Pink1 and
Parkin cause autosomal recessive early-onset Parkinson’s
disease in humans [1,2]. Together mutations in these
genes account for greater than 50% of familial Parkinson
disease (PD) and ~20% of early-onset sporadic cases
[3-5]. Recent studies on characterizing the function of
Parkin and Pink1 have significantly advanced our under-
standing of PD pathogenesis.
Parkin has E3-ubiquitin ligase activity, and is shown to
degrade abnormally folded proteins [6]. For instance,
Parkin ubiquitinates and degrades proteins such as
CDCrel-1 [7], Parkin-associated endothelin receptor-like
(Pael) receptor [8], a-synuclein [9], synphilin-1 [10], and
cyclin E [11]. Thus, Parkin dysfunction in regulating the
level of other proteins or itself through protein degrada-
tion may contribute to PD pathogenesis.
Pink1 is a mitochondria-localized serine/threonine
kinase [2,12,13]. A recent study suggests that Pink1
directly phosphorylates Parkin [14]. In addition, Pink1
may directly or indirectly induce the phosphorylation of
the HSP75 chaperone TRAP1 [12] and the mitochon-
drial protease HtrA2 [13].
Accumulated evidence supports that Pink1 and Parkin
act together in a common and conserved pathway to
protect mitochondrial integrity (for review, see [15]). For
instance, it is reported that overexpression of Drosophila
Parkin (park) could rescue mitochondrial defects caused
by Pink1 mutations both in Drosophila [16-19] and
mammalian systems [20,21]. Recent studies also indicate
that Pink1-dependent recruitment of Park into mito-
chondria is required for the clearance of damaged mito-
chondria [22-25].
Drosophila melanogaster h a sp r o v e nt ob eap o w e r f u l
model system for understanding the function of PD
genes. Several PD genes such as park, Pink1, LRRK2 and
HtrA1 have orthologs in Drosophila.I n t e r f e r i n gw i t h
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[17-19,26-29]. Genetic studies in Drosophila have begun
to reveal new targets for the development of new thera-
peutic approaches to treat PD. For instance, Pallanck
and colleagues previously conducted a genetic screen to
isolate modifiers of partial lethality caused by complete
loss of park in Drosophila [30]. From ~1400 P-element
insertions affecting less than 10% of the fly genome,
they identified several genes that regulate oxidative
stress and innate immune responses [30].
In this study, we conducted a systematic genetic
screen to isolate park- and/or Pink1-interacting regions
that cover ~80% of the entire fly genome. We generated
a genetic background in which park or Pink1 was
knocked down. The availability of this genetic tool
allowed us to perform a F1 genetic screen to identify
cytological regions on the 2
nd and 3
rd chromosome that
interact with park and/or Pink1. We found that 31 cyto-
logical regions modify both park and Pink1 wing-pos-
ture phenotype. In addition, 21 cytological regions
showed interactions with both Pink1 and park in adult
lethality test. We then selected four cytological regions
for fine mapping, which identified two known PD-inter-
acting genes opa1 and drp1, and three novel PD-inter-
acting genes debra, Pi3K21B and b4GalNAcTA.
Methods
Drosophila stocks
UAS-Pink1-RNAi, UAS-park RNAi and other transgenic
RNAi lines were obtained from the VDRC stock center. A
collection of deficiencies uncovering >92% of cytological
regions on 2
nd and 3
rd chromosomes were obtained from
the Bloomington Drosophila Stock Center. Smaller defi-
ciencies and P-element insertions mapped within large
PD-interacting cytological regions were also obtained from
the Bloomington Drosophila Stock Center. Balancer stocks
CyO,GAL80 and TM3,GAL80 were provided by D.van
Meyel. The park
edpkΔ21/TM3,Sb line was provided by M.
Guo (UCLA). Pink1
B9/FM7,Act-GFP and park
25/TM3,Sb
stocks were provided by T. Fon. Df(2R)b4GalNAcTA
[20.1]
and b4GalNAcTA
4.1 lines were obtained from N. Haines.
Genetics
To knock down Pink1 or park, tubulin-GAL4 (tub-
GAL4) flies were crossed with UAS-Pink1-RNAi or UAS-
park-RNAi flies to ubiquitously express Pink1-RNAi or
park RNAi. Since fly stocks with ubiquitous expression
of Pink1-RNAi or park RNAi under control of tub-GAL4
are not healthy, genetic crosses were performed to gen-
erate UAS-Pink1-RNAi/CyO,GAL80; tub-GAL4/TM3,Sb
and UAS-park-RNAi;tub-Gal4/TM3,Sb,GAL80 stocks, in
which GAL4 is inhibited by GAL80 to prevent the
expression of UAS-Pink1-RNAi or UAS-park-RNAi in
parental stocks [31].
F1 screen was performed by crossing individual defi-
ciency lines from 2
nd and 3
rd chromosome deficiency
kits with UAS-Pink1-RNAi/CyO,GAL80; tub-GAL4/TM3,
Sb or UAS-park-RNAi;tub-Gal4/TM3,Sb,GAL80 flies.
The F1 progeny in Pink1-RNAi background were reared
at 25°, and the F1 progeny in park-RNAi background
were kept at 29°. F1 progeny were collected for 4-6 days
and separated according to their date of eclosion. The
modification of wing-posture phenotype by each defi-
ciency chromosome was scored on post-eclosion day 3
for Pink1 screen and on post-eclosion day 6 for park
screen. Wing posture phenotype in both male and
female F1 flies was scored, and the modifying effect on
penetrance was determined by counting the percentage
of both held-up-wing flies and drooped-wing flies. For
park and Pink1 screen, 212 and 217 deficiencies in the
deficiency kit were screened, respectively.
Selected deficiency lines were also crossed with
Pink1
B9/FM7,Act-GFP female flies. F1 progeny were
scored for the modification of the wing-posture pheno-
type. The F1 progeny were also scored for adult lethality
test.
Analysis of wing phenotype, longevity and fertility
For analysis of abnormal wing phenotype, ~20 flies were
placed per vial. Flies with both wings held-up or
drooped were counted.
For longevity test, flies were collected upon eclosion
and transferred to new vials every 4-6 days. Mortality
was scored daily. The assay was performed in triplicate.
Survival curves were plotted using GraphPad software.
To test fertility of male flies, individual male flies were
crossed with three (w1118) virgin females. After 10 days,
the number of vials with progeny were counted.
Statistical Analysis
Student’s t-test was used for statistical analysis.
Results
Characterization of park and Pink1 knockdown
phenotypes
Previous studies show that loss of park or loss of Pink1
caused similar phenotypes, such as abnormal wing mor-
phology, male sterility, reduced climbing ability,
decreased longevity and loss of dopaminergic neurons
[17-19,29]. To generate a “park-inhibited” or “Pink1-
inhibited” background suitable for systematic F1 genetic
screen, we used the GAL4-UAS system [32] to knock
down the level of Pink1 or park in flies.
Consistent with previous reports [17-19,29], we found
that ubiquitous knockdown of Pink1 or park by expres-
sing UAS-park-RNAi or UAS-Pink1-RNAi transgenes
under control of the tub-GAL4 driver, caused male steri-
lity (compared to 100% fertility in wild-type control,
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fertility, respectively), reduced life span, and abnormal
wing posture (i.e. held up or drooped) (Figure 1). Those
phenotypes resembled that observed in park and Pink1
loss-of-function mutants [17-19,29].
We then tested if the penetrance and severity of above
phenotypes could be enhanced by increasing the expres-
sion level of the UAS-park-RNAi transgene. This was
achieved by elevating temperature, which increases the
activity of GAL4 leading to higher expression of UAS-
transgenes [32]. Indeed, we found that increasing the
expression level of park-RNAi significantly enhanced the
phenotype. The penetrance of wing-posture phenotype
in park knockdown flies was increased from ~2.1% at
25°C to ~22.4% at 29°C. The maximal life span of park
knockdown flies was further reduced from ~67 days at
25°C to ~17 days at 29°C. The fertility of male park
knockdown flies was also reduced from ~44.4% at 25°C
to ~30% at 29°C.
We also examined the effect of increasing the level of
Pink1-RNAi transgene on wing posture, male sterility
and longevity. In Pink1 knockdown flies, the penetrance
of wing-posture phenotype was increased from ~2.9% at
room temperature to ~91% at 29°C. The maximal life
span of Pink1 knockdown flies was reduced from ~55
days at room temperature to ~18 days at 29°C. The fer-
tility of male Pink1 knockdown flies was also decreased
from ~14.3% at room temperature to 0% at 29°C.
F1 screen for modifiers of the park knockdown
phenotype
To identify novel modifiers of the PD pathway, we set
out to conduct a systematic screen to identify cytologi-
cal regions on the 2
nd and 3
rd chromosome that interact
with park (Figure 2).
Prior to the screen, we examined if the park knock-
down mutant background is sensitive to the reduction
in the dosage of known genes in the pathway. We found
that reducing the level of endogenous park substantially
increased the penetrance of the park-RNAi-induced
wing posture phenotype from ~15% (n = 76) (genotype:
park RNAi; +/+) to ~43% (n = 97) (genotype: park
RNAi; park
25/+) (P < 0.05). Since Pink1 and park have
previously been shown to act in a common pathway
[17-19], we also tested if the park knockdown back-
ground is sensitive to a reduction in the level of Pink1.
Indeed, we found that Pink1 heterozygostiy significantly
enhanced the penetrance of the park-RNAi-induced
Figure 1 Knockdown of PD genes induces a wing position phenotype in adult flies. A-C, Ubiquitous knockdown of PD genes in flies
induces an abnormal wing position phenotype (i.e. held up or drooped wing). A. Wild-type wing position in flies carrying only the tub-GAL4
driver. B, A park knockdown fly (i.e. a fly carrying both the tub-GAL4 driver and UAS-park-RNAi transgene). The “held-up” wing position phenotype
was observed when UAS-park-RNAi was ubiquitously expressed under control of the tub-GAL4 driver. C, The “drooped” wing phenotype was
observed in a Pink1 knockdown fly (i.e. a fly carrying both the tub-GAL4 driver and UAS-Pink1-RNAi transgene). D, Survival curves of park
knockdown flies (solid line) and control flies (i.e. flies carrying only the UAS-park transgene) (dashed line). The experiments were performed at 25°
C (green) and 29°C (red). Numbers in brackets represent sample numbers. Error bars represent SEM.
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+/+; park RNAi) to ~40% (n = 32) (genotype: Pink1
B9/+;
park RNAi) (P < 0.01).
To systematically identify modifiers of this park wing-
posture phenotype, we crossed a large collection of defi-
ciencies on the 2
nd and 3
rd chromosome into the park
knockdown mutant background. In each deficiency chro-
mosome, a portion of cytological regions was deleted.
Thus, crossing a deficiency chromosome into the park
knockdown background led to 50% reduction in the
dosage of genes located within the deleted cytological
region.
From this screen, we identified 26 cytological regions
that enhanced the park wing-posture phenotype (Table
1), and 53 cytological regions that suppressed the wing-
posture phenotype (Table 2). We also found that redu-
cing the dosage of genes by 50% in 48 cytological
regions in park knockdown flies caused lethality prior to
the adult stage (Table 3). No such adult lethality was
observed when park was knocked down alone, or the
dosage of those 48 cytological regions was reduced by
50% in wild type background.
F1 screen for modifiers of the Pink1 knockdown
phenotype
Above deficiencies were also screened using the Pink1
knockdown mutant background. Pink1 knockdown
mutant flies displayed the wing-posture phenotype at
the penetrance of ~64% (n = 314) at 25°C. Among 26
enhancer-containing cytological regions identified from
the Park screen (Table 1), 8 cytological regions, when
reduced by 50% in dosage, also enhanced the penetrance
of the Pink1 knockdown wing phenotype (Table 4). This
Figure 2 A genetic scheme for isolating modifiers of Parkinson’sd i s e a s eg e n e si nDrosophila. Deficiencies (Df) from the Bloomington
deficiency kits were crossed individually into the park or Pink1 knockdown mutant background. F1 progeny were scored for potential phenotypic
enhancement (i.e. an increase in the penetrance of the wing phenotype) or suppression (i.e. a decrease in the penetrance of the wing
phenotype). Abbreviations: En, enhancement; Su, suppression; tub-GAL4, tubulin-GAL4.
Table 1 Enhancers of the park-RNAi wing phenotype
Deficiencies Breakpoints Strength of modification
a
Df(2L)net-PMF 21A1;21B7-8 ++
Df(2L)BSC28 23C5-D1;23E2 ++++
Df(2L)cl-h3 25D2-4;26B2-5 ++
Df(2L)BSC7 26D10-E1;27C1 ++
Df(2L)ED611 29B4;29C3 ++
Df(2L)BSC17 30C3-5;30F1 ++
Df(2L)Mdh 30D-30F;31F +++++
Df(2L)BSC50 30F5;31B1 ++++++
Df(2L)FCK-20 32D1;32F1-3 +++
Df(2R)nap9 42A1-2;42E6-F1 +++++
Df(2R)cn9 42E;44C ++
Df(2R)H3E1 44D1-4;44F12 +++
Df(2R)en30 48A3-4;48C6-8 +++
Df(2R)BSC39 48C5-D1;48D5-E1 ++++
Df(2R)BSC161 54B2;54B17 ++++
Df(2R)Exel7162 56F11;56F16 ++++
Df(2R)59AD 59A1-3;59D1-4 +++
Df(3L)AC1 67A2;67D11-13 +++++
Df(3L)XS533 76B4;77B ++
Df(3L)BSC249 79B2;79D2 ++
Df(3R)BSC47 83B7-C1;83C6-D1 ++
Df(3R)Tpl10 83C1-2;84B1-2 ++
Df(3R)BSC43 92F7-93A1;93B3-6 ++
Df(3R)BSC56 94E1-2;94F1-2 ++
Df(3R)BSC137 95A2-4;95A8-B1 +++
Df(3R)BSC42 98B1-2;98B3-5 ++
Each deficiency was crossed into the park RNAi background and the wing
posture phenotype was scored. Crosses were maintained at 29°C.
a Each ‘+’ represents 1.0 SD from the mean pentrance (i.e. ~22.4%) observed
for park RNAi alone flies.
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Deficiencies Breakpoints Strength of modification
a
Df(2L)BSC106 21B7;21C2 ++++
Df(2L)dp-79b 22A2-3;22D5-E1 ++++
Df(2L)ed1 24A2;24D4 ++++
Df(2L)sc19-8 24C2-8;25C8-9 ++
Df(2L)BSC110 25C1;25C4 ++
Df(2L)BSC109 25C4;25C8 ++++
Df(2L)E110 25F3-26A1;26D3-11 ++
Df(2L)BSC142 28C3;28D3 ++++
Df(2L)BSC143 31B1;31D9 ++
Df(2L)BSC145 32C1;32C1 +++
Df(2L)b87e25 34B12-C1;35B10-C1 ++++
Df(2L)C’ h35;h38L ++
Df(2R)BSC3 48E12-F4;49A11-B6 ++++
Df(2R)Exel7131 50E4;50F6 ++++
Df(2R)BSC550 53C1;53C6 ++
Df(2R)robl-c 54B17-C4;54C1-4 ++
Df(2R)BSC45 54C8-D1;54E2-7 ++++
Df(2R)P34 55E2-4;56C1-11 ++++
Df(2R)AA21 56F9-17;57D11-12 ++
Df(2R)BSC155 60B9;60C4 +++
Df(2R)M60E 60E2-3;60E11-12 ++
Df(3L)Aprt-1 62A10-B1;62D2-5 ++++
Df(3L)BSC181 62A11;62B7 ++++
Df(3L)XDI98 65A2;65E1 ++
Df(3L)BSC33 65E10-F1;65F2-6 ++
Df(3L)pbl-X1 65F3;66B10 ++++
Df(3L)66C-G28 66B8-9;66C9-10 +++
Df(3L)h-i22 66D10-11;66E1-2 +++
Df(3L)Scf-R6 66E1-6;66F1-6 ++
Df(3L)BSC283 67C7;67D5 +++
Df(3L)eyg[C1] 69A4-5;69D4-6 ++++
Df(3L)BSC10 69D4-5;69F5-7 ++++
Df(3L)BSC12 69F6-70A1;70A1-2 ++
Df(3L)fz-GF3b 70C1-2;70D4-5 +++
Df(3L)XG5 71C2-3;72B1-C1 ++
Df(3L)fz2 75F10-11;76A1-5 ++++
Df(3L)ME107 77F3;78C8-9 +++
Df(3R)ME15 81F3-6;82F5-7 ++
Df(3R)3-4 82F3-4;82F10-11 ++++
Df(3R)p-XT103 85A2;85C1-2 ++++
Df(3R)BSC38 85F1-2;86C7-8 ++
Df(3R)sbd105 88F9-89A1;89B9-10 ++
Df(3R)sbd104 89B5;89C2-7 ++
Df(3R)P115 89B7-8;89E7 +++
Df(3R)Exel9012 94E9;94E13 +++
Df(3R)Exel6195 95A4;95B1 ++
Df(3R)Exel9014 95B1;95D1 +++
Df(3R)Exel6196 95C12;95D8 +++
Df(3R)crb-F89-4 95D7-D11;95F15 +++
Df(3R)slo8 96A2-7;96D2-4 ++++
Df(3R)Exel6202 96C9;96E2 +++
Df(3R)Exel6203 96E2;96E6 ++++
Df(3R)B81 99D3;3Rt ++++
a Each ‘+’ represents 0.5 SD from the mean (~22.4%) observed for park
RNAi alone flies.
Table 3 List of deficiencies showing lethal interactions
with park knockdown
Deficiencies Breakpoints
Df(2L)BSC16 21C3-4;21C6-8
Df(2L)ast2 21D1-2;22B2-3
Df(2L)BSC37 22D2-3;22F1-2
Df(2L)dpp[d14] 22E4-F2;22F3-23A1
Df(2L)C144 22F4-23A1;23C2-4
Df(2L)Exel6011 25C8;25D5
Df(2L)N22-14 29C1-2;30C8-9
Df(2L)J2 31B;32A
Df(2L)cact-255rv64 35F-36A;36D
Df(2L)TW137 36C2-4;37B9-C1
In(2R)bw[VDe2L]Cy[R] h42-h43;42A2-3
Df(2R)Np5 44F10;45D9-E1
Df(2R)BSC29 45D3-4;45F2-6
Df(2R)X1 46C;47A1
Df(2R)en-A 47D3;48B2
Df(2R)vg-C 49A4-13;49E7-F1
Df(2R)CX1 49C1-4;50C23-D2
Df(2R)BSC18 50D1;50D2-7
Df(2R)Exel7130 50D4;50E4
Df(2R)Jp1 51D3-8;52F5-9
Df(2R)BSC49 53D9-E1;54B5-10
Df(2R)PC4 55A;55F
Df(2R)Egfr5 57D2-8;58D1
Df(2R)ED4065 60C8;60E8
Df(2R)Kr10 60F1;60F5
Df(3L)M21 62F;63D
Df(3L)HR119 63C2;63F7
Df(3L)GN34 63E6-9;64A8-9
Df(3L)ZN47 64C;65C
Df(3L)vin5 68A2-3;69A1-3
Df(3L)st-f13 72C1-D1;73A3-4
Df(3L)81k19 73A3;74F
Df(3L)W10 75A6-7;75C1-2
Df(3L)ED4978 78D5;79A2
Df(3L)BSC223 79A3;79B3
Df(3R)Exel6144 83A6;83B6
Df(3R)WIN11 83E1-2;84A5
Df(3R)p712 84D4-6;85B6
Df(3R)M-Kx1 86C1;87B1-5
Df(3R)T-32 86E2-4;87C6-7
Df(3R)ry615 87B11-13;87E8-11
Df(3R)ea 88E7-13;89A1
Df(3R)DG2 89E1-F4;91B1-B2
Df(3R)Dl-BX12 91F1-2;92D3-6
Df(3R)e-R1 93B6-7;93D2
Df(3R)Exel6197 95D8;95E5
Df(3R)Espl3 96F1;97B1
Df(3R)IR16 97F1-2;98A
Df(2L)BSC16 21C3-4;21C6-8
Df(2L)ast2 21D1-2;22B2-3
Df(2L)BSC37 22D2-3;22F1-2
Above deficiencies, when crossed into the park knockdown background,
significantly reduced the viability of park knockdown flies (less than five
flies eclosed).
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regions that were not uncovered from the park screen
(Table 4). Among 53 suppressor-containing cytological
regions identified from the park screen (Table 2), we
found that 23 cytological regions also contained sup-
pressors of the Pink1 wing-posture phenotype (Table 5).
In addition, we found that 30 cytological regions, when
reduced by 50% in dosage, suppressed the Pink1 wing
phenotype but not the park wing phenotype (Table 5).
Among 50 cytological regions that caused adult lethal-
ity when their dosage was reduced by 50% in park
knockdown background (Table 3), 21 cytological regions
also displayed a similar lethal interaction with Pink1
knockdown (Table 6). Five cytological regions only
showed lethal interactions with Pink1 but not park
(Table 6).
Analysis of genetic interactions using a Pink1 null mutant
allele
Cytological regions identified from above RNAi-based
screen may contain genes that function in the Pink1/
park pathway, or genes that function in a parallel path-
way that act together with the Pink1/park pathway to
regulate mitochondrial function. To further characterize
these cytological regions, we performed genetic analysis
using a Pink1 null mutant allele to test the potential
interactions between Pink1 and cytological regions that
interact with both Pink1 and park in the above RNAi-
based screen. Among six enhancer-containing cytologi-
cal regions examined, five cytological regions, when
Table 4 Enhancers of the Pink1-RNAi wing phenotype
Deficiencies Breakpoints Strength of modification
a
Df(2L)net-PMF 21A1;21B7-8 ++
Df(2L)BSC4 21B7-C1;21C2-3 ++
Df(2L)BSC16 21C3-4;21C6-8 ++
Df(2L)BSC17 30C3-5;30F1 ++
Df(2L)BSC50 30F5;31B1 +++
Df(2R)nap9 42A1-2;42E6-F1 ++
Df(2R)cn9 42E;44C ++
Df(2R)BSC29 45D3-4;45F2-6 ++
Df(2R)BSC39 48C5-D1;48D5-E1 ++
Df(2R)BSC3 48E12-F4;49A11-B6 +++
Df(2R)BSC22 56D7-E3;56F9-12 ++
Df(3L)BSC27 65D4-5;65E4-6 ++
Df(3L)BSC14 67E3-7;68A2-6 +++
Df(3L)XG5 71C2-3;72B1-C1 +++
Df(3L)ED4782 75F2;76A1 ++
Df(3L)HD1 79D3-E1;79F3-6 ++
Df(3R)BSC47 83B7-C1;83C6-D1 ++
Df(3R)Tpl10 83C1-2;84B1-2 ++
Each deficiency was crossed into the Pink1 knockdown background and the
wing posture phenotype was scored. Crosses were maintained at 25°C.
a Each ‘+’ represents 1.0 SD from the mean (i.e. ~64.5%) observed for Pink1
RNAi alone flies. Deficiencies that also enhanced park RNAi wing posture
phenotype (Table 1) are indicated in bold.
Table 5 Suppressors of the Pink1-RNAi wing phenotype
Deficiencies Breakpoints Strength of modification
a
Df(2L)BSC106 21B7;21C2 +++
Df(2L)dp-79b 22A2-3;22D5-E1 +++++
Df(2L)JS17 23C1-2;23E1-2 +++
Df(2L)drm-P2 23F3-4;24A1-2 +++
Df(2L)ed1 24A2;24D4 +++
Df(2L)BSC109 25C4;25C8 ++++
Df(2L)E110 25F3-26A1;26D3-11 ++++
Df(2L)BSC6 26D3-E1;26F4-7 ++++
Df(2L)Dwee1-W05 27C2-3;27C4-5 +++
Df(2L)XE-3801 27E2;28D1 +++
Df(2L)BSC142 28C3;28D3 ++++
Df(2L)BSC143 31B1;31D9 +++
Df(2L)BSC32 32A1-2;32C5-D1 +++++
Df(2L)BSC147 34C1;34C6 ++++
Df(2L)Exel6049 40A5;40D3 +++
Df(2R)w45-30n 45A6-7;45E2-3 ++++
Df(2R)CB21 48E;49A +++
Df(2R)Exel7130 50D4;50E4 ++++
Df(2R)Exel7131 50E4;50F6 +++++
Df(2R)BSC11 50E6-F1;51E2-4 +++
Df(2R)BSC550 53C1;53C6 ++++
Df(2R)robl-c 54B17-C4;54C1-4 +++
Df(2R)k10408 54C1-4;54C1-4 +++
Df(2R)P34 55E2-4;56C1-11 ++++
Df(2R)Exel7162 56F11;56F16 +++
Df(2R)or-BR6 59D5-10;60B3-8 +++
Df(3L)M21 62F;63D +++
Df(3L)GN34 63E6-9;64A8-9 +++
Df(3L)XDI98 65A2;65E1 +++
Df(3L)BSC33 65E10-F1;65F2-6 +++
Df(3L)66C-G28 66B8-9;66C9-10 +++
Df(3L)BSC13 66B12-C1;66D2-4 +++
Df(3L)Scf-R6 66E1-6;66F1-6 +++++
Df(3L)BSC10 69D4-5;69F5-7 +++
Df(3L)st-f13 72C1-D1;73A3-4 ++++
Df(3L)81k19 73A3;74F +++++
Df(3L)kto2 76B1-2;76D5 +++
Df(3L)ri-79c 77B-C;77F-78A ++++
Df(3L)ri-XT1 77E2-4;78A2-4 ++++
Df(3L)ME107 77F3;78C8-9 +++
Df(3L)BSC249 79B2;79D2 ++++
Df(3R)p-XT103 85A2;85C1-2 +++++
Df(3R)M-Kx1 86C1;87B1-5 ++++
Df(3R)ea 88E7-13;89A1 +++
Df(3R)sbd104 89B5;89C2-7 +++
Df(3R)P115 89B7-8;89E7 ++++
Df(3R)23D1 94A3-4;94D1-4 +++
Df(3R)crb-F89-4 95D7-D11;95F15 +++
Df(3R)Exel6197 95D8;95E5 +++
Df(3R)Exel6202 96C9;96E2 +++
Df(3R)Exel6203 96E2;96E6 ++++
Df(3R)Tl-P 97A;98A1-2 +++
Df(3R)IR16 97F1-2;98A +++++
a Each ‘+’ represents 1.0 SD from the mean (i.e. ~64.5%) observed for
Pink1 RNAi alone flies. Deficiencies that also suppressed the park RNAi
wing posture phenotype (Table 2) are indicated in bold.
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Page 6 of 12reduced by 50% in dosage, also enhanced the wing phe-
notype in Pink1 null mutants (Table 7). Among 17 sup-
pressor-containing cytological regions examined, 10
cytological regions, when reduced by 50% in dosage,
also suppressed the wing phenotype in Pink1 null
mutants (Table 7). Among 19 examined cytological
regions that showed lethal interactions with both Pink1
and park in RNAi-based screens, 5 cytological regions,
when reduced by 50% in dosage, also displayed the
lethal phenotype in Pink1 null mutants (Table 8).
Molecular characterization of the PD-interacting
cytological region 21A1-21B7
The PD-interacting cytological regions identified from
above screens are relative large and contain a number of
genes. As a first step towards molecular characterization
of these PD-interacting cytological regions, we per-
formed fine mapping in four selected PD-interacting
cytological regions to identify corresponding PD-inter-
acting genes. Those cytological regions were selected
s i n c et h e yd i s p l a y e ds t r o n g e st interactions with both
park and Pink1.
From above screens, we found that reducing the
dosage of the cytological region 21A1-21B7-8, deleted in
the deficiency chromosome Df(2L) net-PMF, enhanced
both park and Pink1 wing phenotype (Table 1 and 4).
To identify the corresponding PD-interacting gene
within this cytological region, we tested additional defi-
ciency lines that carry smaller deletions within this
region. We found that similar enhancement was
observed when a smaller deficiency chromosome Df(2L)
Table 6 List of deficiencies showing lethal interactions
with Pink1 knockdown
Deficiencies Breakpoints
Df(2L)BSC37 22D2-3;22F1-2
Df(2L)dpp[d14] 22E4-F2;22F3-23A1
Df(2L)C144 22F4-23A1;23C2-4
Df(2L)sc19-8 24C2-8;25C8-9
Df(2L)Exel6011 25C8;25D5
Df(2L)b87e25 34B12-C1;35B10-C1
Df(2L)TW137 36C2-4;37B9-C1
In(2R)bw[VDe2L]Cy[R] h42-h43;42A2-3
Df(2R)M41A4 41A;41A
Df(2R)X1 46C;47A1
Df(2R)CX1 49C1-4;50C23-D2
Df(2R)BSC49 53D9-E1;54B5-10
Df(2R)ED4065 60C8;60E8
Df(2R)Kr10 60F1;60F5
Df(3L)HR119 63C2;63F7
Df(3L)vin5 68A2-3;69A1-3
Df(3L)vin7 68C8-11;69B4-5
Df(3L)W10 75A6-7;75C1-2
Df(3L)ED4978 78D5;79A2
Df(3L)BSC223 79A3;79B3
Df(3R)Exel6144 83A6;83B6
Df(3R)p712 84D4-6;85B6
Df(3R)T-32 86E2-4;87C6-7
Df(3R)DG2 89E1-F4;91B1-B2
Df(3R)Dl-BX12 91F1-2;92D3-6
Df(3R)B81 99D3;3Rt
Above deficiencies, when crossed into the Pink1 knockdown background,
significantly reduced the viability of Pink1 knockdown flies (less than five flies
eclosed). Deficiencies that display a similar lethal interaction with park
knockdown (Table 3) are indicated in bold.
Table 7 Analysis of the interaction between a Pink1 null
mutation and cytological regions that modified both
park-RNAi and pink1-RNAi wing phenotype
Effects of modification
Deficiencies Breakpoints Pink1-RNAi park-RNAi Pink1
B9
Enhancers
Df(2L)net-PMF 21A1;21B7-8 ++ ++ n/d
Df(2L)BSC17 30C3-5;30F1 ++ ++ n/d
Df(2L)BSC50 30F5;31B1 +++ ++++++ En
Df(2R)nap9 42A1-2;42E6-F1 ++ +++++ En
Df(2R)cn9 42E;44C ++ ++ En
Df(2R)BSC39 48C5-D1;48D5-E1 ++ ++++ En
Df(3R)BSC47 83B7-C1;83C6-D1 ++ ++ En
Df(3R)Tpl10 83C1-2;84B1-2 ++ ++ No
Suppressors
Df(2L)BSC106 21B7;21C2 —— — Su
Df(2L)dp-79b 22A2-3;22D5-E1 ——— —— No
Df(2L)ed1 24A2;24D4 —— — n/d
Df(2L)BSC109 25C4;25C8 —— —— Su
Df(2L)E110 25F3-26A1;26D3-11 —— – n/d
Df(2L)BSC142 28C3;28D3 —— —— Su
Df(2L)BSC143 31B1;31D9 —– No
Df(2R)Exel7131 50E4;50F6 ——— —— Su
Df(2R)BSC550 53C1;53C6 —— – No
Df(2R)robl-c 54B17-C4;54C1-4 —– n/d
Df(2R)P34 55E2-4;56C1-11 —— —— Su
Df(3L)XDI98 65A2;65E1 —– n/d
Df(3L)BSC33 65E10-F1;65F2-6 —– n/d
Df(3L)66C-G28 66B8-9;66C9-10 —— No
Df(3L)Scf-R6 66E1-6;66F1-6 ——— – Su
Df(3L)BSC10 69D4-5;69F5-7 —— — Su
Df(3L)ME107 77F3;78C8-9 —— No
Df(3R)p-XT103 85A2;85C1-2 ——— —— Su
Df(3R)sbd104 89B5;89C2-7 —– n/d
Df(3R)P115 89B7-8;89E7 —— — Su
Df(3R)crb-F89-4 95D7-D11;95F15 —— No
Df(3R)Exel6202 96C9;96E2 —— No
Df(3R)Exel6203 96E2;96E6 —— —— Su
Abbreviations: n/d, not determined; Su, suppression; En, enhancement; No, no
modification.
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background (Figure 3). Twenty two genes are disrupted
in this deficiency chromosome, including dbr, galectin,
CG11374, net, CG11376, Sam-S, CG4822, Gs1,
CG31976, CG3709, CG11377, CG13694, CG31975,
CG11455, Nhe1, CG3164, CG31974, CG3436, CG11454,
CG33635, CG42399 and spen. Interestingly, we found
that another smaller deficiency Df(2L) ED2809 in which
only the debra (dbr) gene is deleted, also enhanced the
park knockdown phenotype (~50% increase in pene-
trance compared to park RNAi alone, n = 104). Taken
together, these results suggest strongly that dbr is lar-
gely, if not entirely, responsible for the observed interac-
tion with PD genes.
Molecular characterization of two PD suppressor-
containing cytological regions 21B7-21C2 and 50E4-50F6
Reducing the dosage of the cytological region 21B7-21C2,
uncovered by the deficiency chromosome Df(2L)BSC106,
suppressed both park and Pink1 wing phenotype (Table
2 and 5). From a collection of smaller deficiencies
mapped within this region, we identified two overlapping
deficiencies Df(2L)BSC454 and Df(2L)Pi3K21B, which like
Df(2L)BSC106,b o t hs u p p r e s s e dpark and Pink1 wing
phenotype (Figure 4A). The cytological region deleted in
both Df(2L)BSC454 and Df(2L)Pi3K21B,c o n t a i n sf o u r
genes Hop, Pi3K21B, Plc21C and U2af38.
To further narrow down the PD-interacting gene
within this region, we tested if any of above four genes
interacts with PD genes. Among them, we found that
knockdown the expression of Pi3K21B also significantly
suppressed the Pink1 wing phenotype (~48% decrease in
penetrance compared to Pink1 RNAi alone, n = 42).
This result suggests that Pi3K21B is the corresponding
PD-interacting gene.
Reducing the dosage of the cytological region 50E4-
50F6, uncovered by the deficiency chromosome Df(2R)
Exel7131, also suppressed both park and Pink1 knock-
down wing phenotype (Table 2 and 5). However,
another deficiency Df(2R)BSC700, in which the deleted
cytological region partially overlaps with that affected in
Df(2R)Exel7131, did not interact with park or Pink1.
The cytological region deleted in Df(2R)Exel7131,b u t
not in Df(2R)BSC700, carry nine genes (i.e. opa1-like,
CG8485, CG8494, CG8503, Mdr50, Hsc70-5, CG8531,
b4GalNAcTA and CG8547) (Figure 4B).
To test if the above genes interact with park or Pink1,
we crossed available mutations into park or Pink1
knockdown background. We found that opa1 and
b4GalNAcTA interact genetically with PD genes (Figure
4B). A heterozygous mutation of opa1 (i.e. opa1
EY09863)
significantly suppressed the park wing phenotype (~95%
reduction in penetrance compared to park knockdown
alone, n = 83). And heterozygous mutations of b4Gal-
NAcTA, Df (2R)b4GalNAcTA
[20.1] (deleting both b4Gal-
NAcTA and its neighboring gene CG8547)a n d
b4GalNAcTA
4.1 (deleting part of the b4GalNAcTA gene
only), significantly suppressed the Pink1 wing phenotype
(for Df (2R)b4GalNAcTA
[20.1], ~92% reduction in pene-
trance compared to Pink1 knockdown alone, n = 62; for
b4GalNAcTA
4.1, ~82% reduction in penetrance com-
pared to Pink1 knockdown alone, n = 59).
Table 8 Analysis of the interaction between a Pink1 null
allele and deficiencies that exhibited lethal interactions
with both park and Pink1 knockdown
Deficiencies Breakpoints Synthetic lethal
with pink1
B9
Df(2L)BSC37 22D2-3; 22F1-2 No
Df(2L)dpp[d14] 22E4-F2; 22F3-23A1 Yes
Df(2L)C144 22F4-23A1; 23C2-4 Partial
Df(2L)Exel6011 25C8; 25D5 No
Df(2L)TW137 36C2-4; 37B9-C1 No
In(2R)bw[VDe2L]Cy[R] h42-h43;42A2-3 Yes
Df(2R)M41A4 h44;42A2 Yes
Df(2R)X1 46C;47A1 n/d
Df(2R)CX1 49C1-4;50C23-D2 Yes
Df(2R)BSC49 53D9-E1;54B5-10 No
Df(2R)ED4065 60C8;60E8
Df(2R)Kr10 60F1;60F5 No
Df(3L)HR119 63C2;63F7 No
Df(3L)vin5 68A2-3;69A1-3 No
Df(3L)vin7 68C8-11;69B4-5 No
Df(3L)W10 75A6-7;75C1-2 No
Df(3L)ED4978 78D5;79A2 No
Df(3L)BSC223 79A3;79B3 No
Df(3R)Exel6144 83A6;83B6 No
Df(3R)p712 84D4-6;85B6 n/d
Df(3R)T-32 86E2-4;87C6-7 No
Df(3R)Dl-BX12 91F1-2;92D3-6 No
Figure 3 Molecular characterization of the PD-interacting
cytological region 21A1-21B7. Genes (arrows) are listed according to
their genomic location. The regions uncovered by the deficiencies used
in the experiments are indicated (dashed lines). The effect of each
deficiency is indicated as enhancement (+) or no enhancement (-).
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Page 8 of 12drp1 is the corresponding gene of the cytological region
22F4-23A3 that displayed lethal interaction with PD
genes
Two deficiencies, Df(2L)dpp
[d14] (22E4-F2;22F3-23A1)
and Df(2L)C144 (22F4-23A1;23C2-4), caused lethality
when heterozygous in park RNAi, Pink1 RNAi or Pink1
null mutant background (Table 8). A smaller deficiency
(i.e. Df(2L)ED136), which deletes the overlapping region
defined by the above deficiencies,a l s oc a u s e dp a r t i a l
lethality in the Pink1 null background (i.e. ~50% reduc-
tion in viability compared to controls). The cytological
region deleted in Df(2L)ED136 contains 29 genes, of
which mutations in drp1 have been previously impli-
cated as an enhancer of park and Pink1 mutant pheno-
types [16,33,34]. Hence, we used a mutant allele for
drp1 (i.e. drp1
KG03815) to examine the potential interac-
tion. Consistent with previous reports, we found that
drp1 heterozygosity substantially enhanced the lethal
phenotype in the Pink1 null background (i.e. ~82.8%
reduction in viability compared to controls). This result
strongly suggests that drp1 is the corresponding gene
within the cytological region 22F4-23A3 that displayed
lethal interaction with PD genes.
Discussion
In this study, we performed a genome-wide screen to
isolate modifiers of PD genes. From this screen, we
identified a number of cytological regions that interact
with park and/or Pink1. Fine mapping of selected PD-
interacting cytological regions led to the identification of
corresponding PD-interacting genes. Among them, opa1
and drp1 have previously been implicated in Pink1/
park-mediated mitochondrial quality control pathways.
In addition, we also identified debra, Pi3K21B,a n d
b4GalNAcTA as novel PD-interacting genes.
While several previous studies suggest that park and
Pink1 function in a common pathway to regulate mito-
chondrial function, cytological regions identified from
our park-a n dPink1-modifying screens do not comple-
tely overlap. For instance, among cytological regions
showing lethal interactions with Pink1, about 81% dis-
played similar interactions with park (Table 6). Among
Figure 4 Molecular characterization of two PD suppressor-containing cytological regions 21B7-21C2 and 50E4-50F6. A, Characterization
of the PD-interacting cytological region 21B7-21C2. B, Characterization of the PD-interacting cytological region 50E4-50F6. The regions
uncovered by the deficiencies used in the experiments are indicated (dashed line). The effect of each deficiency is indicated as suppression (+) or
no suppression (-). The genes (arrows) are listed according to their genomic location. opa1
EY09863 is an opal loss-of-function allele in which a P-
element-containing sequence is inserted into the opa1 locus. Df(2R)b4GalNAcTA
[20.1] and b4GalNAcTA
4.1 were generated by imprecise excision
[47]. In the Df(2R)b4GalNAcTA
[20.1] allele, both b4GalNAcTA and CG8531 are deleted, while 610 base-pair sequence in the b4GalNAcTA gene is
deleted in the b4GalNAcTA
4.1 allele.
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only ~44% showed similar interactions with park (Table
4 and 5). One possible explanation is that park and
Pink1 knockdown genetic background have different
sensitivity, which may account for the difference in their
interactions with some cytological regions. Alternatively
or additionally, the molecular network involving Park
and Pink1 may be more complex than a simplified linear
pathway.
A previous study by Pallanck and colleagues screened
a collection of P-element insertions (covering less than
10% of the fly genome) that modify the partial lethality
of park null mutants [30]. However, since their screen
was conducted in homozygous park null mutant back-
ground, less than 10% of the fly genome was covered.
To increase the coverage, we developed an RNAi-based
strategy, which allowed us to perform a F1 screen that
covered >80% of the fly genome. Several PD-interacting
genes identified by Pallanck and colleagues in their pre-
vious screen [30], are located within PD-interacting
cytological regions identified from our screen. For
instance, Glutathione S-transferase 1( Gst1)a n dThiore-
doxin-2 (Trx-2) are located in PD-interacting cytological
regions uncovered by Df(2R)BSC49 (Table 6) and Df(2L)
N22-14 (Table 3), respectively.
While our screen using deficiencies greatly increases
the coverage of genomic regions, there are several lim-
itations. For instance, since cytological regions deleted
in deficiency chromosomes contain a large number of
genes (average ~50), it is possible that a cytological
region containing PD-interacting genes may not be
identified from our screen if both enhancers and sup-
pressors are located within the same region. Similarly,
this may also make it difficult to identify the corre-
sponding genes, especially if the strong modifying effect
is due to the presence of multiple weak modifiers within
the same region. Additionally, since those deficiency
chromosomes used in our screen may carry second-site
mutations contributing to the observed interactions, it is
necessary to characterize independent point mutations
and/or deletions mapped within the same region.
Our screen isolated two known PD-interacting genes
drp1 and Opa1. drp1 encodes a GTPase (i.e. the dyna-
min-related protein 1) that has been previously impli-
cated in regulating mitochondrial fission [35], while
opa1 (optic atrophy 1) encodes for another dynamin-
related GTPase that promotes mitochondrial fusion
[36,37]. Consistent with previous reports [16,33,34], we
showed that drp1 heterozygosity induced lethality prior
to the adult stage in park or Pink1 knockdown back-
ground. We also showed that opa1 heterozygosity signif-
icantly suppressed the park-RNAi-induced wing
phenotype. Similarly, previous reports showed that het-
erozygous mutations of opa1 suppressed indirect flight
muscle degeneration and mitochondrial morphological
phenotypes in Pink1 and park mutants [33,34].
Together, these observations underscore the importance
of PD-interacting genes in mitochondrial fission and
fusion to facilitate mitochondrial quality control.
Among the three novel PD-interacting genes (i.e.
debra, Pi3K21B,a n db4GalNAcTA)i s o l a t e df r o mo u r
screen, debra (determiner of breaking down of Ci acti-
vator) (dbr) heterozygosity led to strong enhancement of
the park-RNAi-induced wing phenotype. dbr encodes a
novel zinc-binding protein of 1007 amino-acid residues
[38]. Cell culture studies showed that Dbr forms a com-
plex with Slimb, a component of the SCF (Skpl, Cdc53
and F box) ubiquitin ligase complex, to mediate the
polyubiquitination of the transcription factor Cubitus
interruptus (Ci) and thus targets Ci into the lysosome
for degradation [38]. This raises the interesting possibi-
lity that Dbr functions together with Park in the ubiqui-
tin-proteasome pathway for the control of protein
quality. Reducing the dosage of dbr may thus increase
the accumulation of toxic protein substrates, leading to
the enhancement of the park phenotype. In this context,
it is worth noting that a recent study showed that redu-
cing the level of dbr also enhanced Ataxin3-induced
neurodegeneration in Drosophila, which also resulted
from accumulation of pathogenic proteins [39]. Addi-
tionally, since Dbr is a zinc-binding protein, Dbr may
also play a role in regulating the level of intracellular
zinc. Zinc dyshomeostasis has been shown to cause
abnormalities in autophagy that are associated with Alz-
heimer’s disease, Parkinson’s disease, and Huntington’s
disease [40]. Thus, it is possible that in addition to its
interaction with Park in the ubiquitin-proteasome path-
way, Dbr may interact with the PD pathway by regulat-
ing autophagy.
Another novel-PD-interacting gene Pi3K21B,i d e n t i -
fied in our screen as a suppressor of PD wing pheno-
type, encodes an SH2 domain-containing adaptor
protein that binds to the Drosophila class IA Phosphoi-
nisitide 3 Kinase (PI3K), Pi3K92E/Dp110 [41]. It has
been shown that class IA PI3-kinases are activated by
nutrient-responsive insulin signalling to regulate cell
growth and proliferation [42]. Loss of Pi3K21B-binding
sites completely abrogates the activation of Dp110 by
the insulin receptor, which decreased cell growth lead-
i n gt or e d u c e db o d ys i z e[ 4 3 ] .O n ep o s s i b l ee x p l a n a t i o n
for the observed interaction between Pi3K21B and PD
g e n e si st h a tr e d u c i n gt h el e v e lo fPi3K21B may
decrease insulin signaling and metabolic activities. This
may be achieved by reducing the level of the TOR (tar-
get of rapamycin) signaling pathway. TOR can be acti-
vated by the PI3K/Akt pathway to regulate cell growth
and metabolism (for review, see [44]). Recent studies
show that reducing TOR signaling rescued PD
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mediated 5’-Cap-dependent translation [45], and
increasing 4E-BP-promoted 5’-Cap-independent transla-
tion [46]. Similarly, we speculate that Pi3K21B hetero-
zygosity promotes 5’-Cap-independent translation by
reducing TOR signaling, thus increasing the production
of pro-survival factors leading to the suppression of PD
phenotypes.
Characterization of the suppressors of the Pink1-
RNAi-induced wing phenotype also identified b4Gal-
NAcTA as a novel PD-interacting gene. b4GalNAcTA
encodes for a b 1,4-N acetlygalactosaminyltransferase
that mediates the N-glycosylation of protein substrates
[47]. Drosophila adult mutants of b4GalNAcTA display
severe locomotion abnormalities such as a low climbing
index and coordination defects [48]. Glycosylation may
affect protein function by diverse mechanisms, such as
promoting protein stability, enabling protein recogni-
tion, altering ligand affinity and inhibiting protein activ-
ity [49]. For instance, abnormal glycosylation of alpha-
dystroglycan interferes with its function leading to con-
genital muscular dystrophy [50]. Glycosylation may also
contribute to the misfolding and accumulation of several
proteins implicated in neurodegenerative disorders. For
instance, glycosylation of tau and amyloid precursor
protein (APP) may promote the formation and accumu-
lation of pathogenic advanced glycosylation end-pro-
ducts (AGEs) [51]. In addition, a-synuclein, the primary
component of Lewy bodies in Parkinson’s disease, is
also modified by glycosylation [9]. This modification is
hypothesized to affect the clearance of a-synuclein
aggregates [9]. We speculate that glycosylation mediated
by b4GalNAcTA affects the stability and/or activity of
components in the PD pathways, which may contribute
to the accumulation of toxic proteins, increased sensitiv-
ity to oxidative damage and mitochondrial dysfunction.
Future studies will be needed to elucidate the exact
action of b4GalNAcTA in the PD pathways.
Conclusion
Systematic genetic screens covering ~80% of the entire
genome were performed to identify modifiers of the PD
phenotype in Drosophila. From the screen, we identified
a number of cytological regions that interact with park
and/or Pink1. Fine mapping in selected PD-interacting
cytological regions was performed, which identified
debra, Pi3K21B and b4GalNAcTA as novel PD-interact-
ing genes. Future characterization of other PD-interact-
ing cytological regions will likely lead to the
identification of additional PD-interacting genes.
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